References
- E Chu, VT DeVita Jr, eds. Physicians’ Cancer Chemotherapy Drug Manual; Boston, MA: Jones and Bartlett. 2006.
- C Mercier, and J Ciccolini. 2006. Profiling dihydropyrimidine dehydrogenase deficiency in patients with cancer undergoing 5-fluorouracil/capecitabine therapy. Clin Colorectal Cancer 6 (4):288–296.
- M Johnson, and RB Diasio. 2001. Importance of dihydropyrimidine dehydrogenase (DPD) deficiency in patients exhibiting toxicity following treatment with 5-fluorouracil. Adv Enzyme Regul 41:151–157.
- LK Mattison, J Fourie, RA Desmond, A Modak, MW Saif, and RB Diasio. 2006. Increased prevalence of dihydropyrimidine dehydrogenase deficiency in African-Americans compared with Caucasians. Clin Cancer Res 12 (18):5491–5495.
- P Narasimham, S Narasimhan, IF Hitti, and M Rachita. 2004. Serious hand-and-foot syndrome in black patients treated with capecitabine: report of 3 cases and review of literature. Cutis 73 (2):101–106.
- MW Saif, and AA Elfiky. 2007. Identifying and treating fluoropyrimidine-associated hand-and-foot syndrome in white and non-white patients. J Support Oncol 5 (7):337–343.
- JJ Grau, M Caballero, M Monzó, C Muñoz-García, J Domingo-Domenech, A Navarro, C Conill, M Campayo, and JA Bombí. 2008. Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J Surg Oncol 98 (2):130–134.
- JS MacDonald, SR Smalley, J Benedetti, and et al 2001. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725–730.
- Roche. 2008. http://www.rocheusa.com/products/xeloda. Last assessed on Aug 26, 2008.